Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAetna Allergy and Hypersensitivity Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0038

    Allergy and Hypersensitivity

    Customize your policy alerts

    Sign up for Aetna Policy 0038 alerts

    Get alerted when Policy 0038 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna clinical policy bulletin defining medical necessity criteria for allergy and hypersensitivity testing, immunotherapy, selected other treatments (desensitization, epinephrine kits, aspirin desensitization), and listing tests/treatments considered experimental/investigational; includes CPT/HCPCS/ICD-10 coding guidance and limits.

    Policy Summary
    PayerAetna
    PolicyAllergy and Hypersensitivity
    Policy CodePolicy 0038
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 8, 2024
    Next Review Date
    Key ActionEnsure testing meets Aetna's medical necessity criteria: symptoms uncontrolled by conservative therapy; correlation to history/exposure/physical findings; and test technique/allergen proven effective in peer-reviewed literature.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical/coverage changes — this brief indicates has_material_change = false and contains no policy changes.

    40/12Initial in vitro test screen limits (inhalant/food)
    70/40Max percutaneous/intracutaneous inhalant tests (typical)
    14Max SET titration tests
    80Max additional IDT injections if positive
    1OIT trials show increased anaphylaxis risk
    OFCDiagnostic Standard

    Coverage Summary

    This policy (Aetna Clinical Policy Bulletin Number 0038) defines medical necessity criteria and coverage limits for allergy and hypersensitivity testing and treatments, and lists tests/treatments considered experimental or investigational. It distinguishes covered procedures (e.g., percutaneous and intradermal skin testing, in vitro IgE testing, patch/photo testing, bronchial/exercise/ingestion challenge, SET for selected patients, allergy immunotherapy when criteria met) from non‑covered/experimental services (many unvalidated assays and novel immunotherapies).

    Key program limits include an initial in vitro IgE screen of up to 40 inhalant tests or 12 food/other tests, typical maximum testing volumes of up to 70 percutaneous tests followed by up to 40 intracutaneous tests for inhalant evaluation, and SET (IDT) up to 14 titration tests (with an additional 40 antigens or 80 IDT injections potentially medically necessary if initial results are positive). Percutaneous CPT codes (e.g., 95004/95017/95018) are noted and are not covered after allergen immunotherapy unless criteria are met.

    The policy includes operational and documentation requirements (medical history, exam, test results, treatment plan and injection records) and coding guidance (covered CPT/HCPCS and listed experimental codes). Policy administrative metadata: policy number 0038; Effective date 07/21/1995; Last review 02/08/2024; Next review listed as 01/11/2024.

    Medical-Necessity Criteria

    Medical Necessity - Allergy Testing (general)

    Aetna considers specific allergy testing medically necessary for members with clinically significant allergic history of symptoms when ALL of the following criteria are met:

    Policy Summary
    PayerAetna
    PolicyAllergy and Hypersensitivity
    Policy CodePolicy 0038
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 8, 2024
    Next Review Date
    Key ActionEnsure testing meets Aetna's medical necessity criteria: symptoms uncontrolled by conservative therapy; correlation to history/exposure/physical findings; and test technique/allergen proven effective in peer-reviewed literature.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaNot Covered / Experimental Tests and TreatmentsCodingProvider Actions and Operational RequirementsBackground and Evidence SummaryDefinitionsThresholds and Diagnostic InterpretationRevision History
    Symptoms are not adequately controlled by empiric conservative therapy; and
    Testing must correlate specifically to the member's history, risk of exposure and physical findings; and
    Test technique and/or allergens tested must have proven efficacy demonstrated through scientifically valid medical studies published in the peer-reviewed literature.

    Epicutaneous (scratch, prick or puncture) testing

    Epicutaneous (scratch, prick or puncture) testing is considered medically necessary when IgE-mediated reactions are suspected and testing matches the clinical history. Perform percutaneous testing for:

    Foods
    Hymenoptera (stinging insects)
    Inhalants
    Specific drugs (e.g., penicillins and macromolecular agents)

    Intradermal (Intracutaneous) testing

    Intradermal (intracutaneous) testing is considered medically necessary when IgE-mediated reactions are suspected for selected allergens and when percutaneous tests are negative or insufficient. Do not use intradermal testing for food allergy.

    Hymenoptera venom allergy (stinging insects)
    Inhalants
    Specific drugs (e.g., penicillins and macromolecular agents)

    Number limits - Epicutaneous and Intracutaneous

    Typical number limits for skin testing (may vary by clinical need):

    Evaluation of inhalant allergy may require up to 70 percutaneous (epicutaneous) tests.
    Follow-up intracutaneous testing may include up to 40 intradermal tests (often performed when percutaneous tests are negative).
    When determining starting dose for immunotherapy in highly allergic patients, up to 14 skin endpoint titration (SET) dilutional tests may be necessary; an additional 40 antigens or up to 80 IDT injections may be medically necessary if initial results are positive.

    Skin Endpoint Titration (SET / IDT)

    Skin Endpoint Titration (SET / IDT) — also called intradermal dilutional testing — is used to determine the starting dose for immunotherapy in highly allergic individuals.

    Members highly allergic to hymenoptera venom (stinging insects).
    Members highly allergic to inhalants.
    When used to determine starting dose for immunotherapy, up to 14 titration tests may be necessary; if any initial titration test is positive, an additional 40 antigens or up to 80 IDT injections may be medically necessary.
    SET is inappropriate as a substitute for standard skin testing; use only when needed to establish a safe starting concentration for immunotherapy.

    Skin Patch Testing

    Patch testing is considered medically necessary for diagnosing allergic contact dermatitis.

    Skin patch testing for contact dermatitis (up to 80 units is considered medically necessary).

    Photo Patch Testing and Photo Tests

    Photo-patch testing and photo tests are used to evaluate photo-allergy and photosensitivity disorders.

    Photo-patch testing for diagnosing photo-allergic contact dermatitis.
    Phototests for evaluating photosensitivity disorders.

    Bronchial Challenge Test

    Bronchial challenge testing (e.g., methacholine, histamine, or antigen) is used to define asthma or airway hyperreactivity when indicated.

    When bronchial challenge testing is being used to identify new allergens for which skin or blood testing has not been validated.
    When skin testing is unreliable or cannot be performed.

    Exercise Challenge Testing

    Exercise challenge testing is medically necessary for diagnosis of exercise-induced bronchospasm.

    Evaluation of exercise-induced bronchospasm (exercise challenge testing).

    Ingestion (Oral) Challenge Test

    Ingestion (oral) challenge testing is considered medically necessary for evaluation of suspected food or other non-drug reactions and for certain drug challenges when strict conditions are met.

    Food or other substances (e.g., metabisulfite).
    Drugs when ALL of the following are met:
    History of allergy to the particular drug; and
    There is no effective alternative drug; and
    Treatment with that drug class is essential.

    In Vitro IgE Antibody Tests

    In vitro IgE antibody tests (e.g., RAST, MAST, FAST, ELISA, ImmunoCAP) are medically necessary in specific clinical scenarios and may be used as an initial screen in lieu of skin testing within limits.

    Indications for in vitro testing: patients on skin-test–suppressive medications that cannot be discontinued; widespread skin disease (dermatographism, generalized eczema); uncooperative patients (small children, impaired individuals); history suggesting high anaphylaxis risk with skin testing; evaluating cross-reactivity between insect venoms; adjunctive testing for ABPA or certain parasitic diseases.
    Initial allergy screen limits: up to 40 inhalant tests and up to 12 food/other tests. Additional tests may be medically necessary if any initial test is positive; if all initial tests are negative, further in vitro testing beyond the initial screen is not considered medically necessary.
    Operational notes: use in vitro testing when skin testing is contraindicated or impractical (medication suppression, skin disease, patient inability). Ensure testing correlates with clinical history and document reasons why skin testing could not be performed.

    Total Serum IgE

    Total serum IgE measurement (e.g., PRIST, RIST) is used in specific diagnostic evaluations.

    Diagnostic evaluation for known or suspected allergic bronchopulmonary aspergillosis (ABPA).
    Evaluation for hyper IgE syndrome.

    Lymphocyte Transformation Tests

    Lymphocyte transformation tests have limited allergy indications but are useful for specific non-allergy diagnoses.

    Medically necessary: evaluation of persons with sensitivity to beryllium.
    Medically necessary: evaluation of congenital or acquired immunodeficiency diseases affecting cell-mediated immunity (examples: severe combined immunodeficiency, common variable immunodeficiency, X-linked hyper IgM, Nijmegen breakage syndrome, reticular dysgenesis, DiGeorge syndrome, Nezelof syndrome, Wiscott-Aldrich syndrome, ataxia telangiectasia, chronic mucocutaneous candidiasis).
    Medically necessary: evaluation in thymoma or to predict allograft compatibility in transplant setting.
    Experimental/investigational: lymphocyte transformation tests are considered experimental and investigational for evaluation of persons with allergies or other hypersensitivities (including metal allergy testing).

    Alpha-Gal (Meat) Allergy Testing

    Alpha-gal (galactose-alpha-1,3-galactose) IgE testing is medically necessary when clinical presentation after mammalian meat ingestion meets specified criteria.

    Testing is medically necessary when EITHER of the following occur within 3–6 hours after ingestion of mammalian meat:
    Urticaria, angioedema, or anaphylaxis.
    Gastrointestinal symptoms (abdominal pain, diarrhea, vomiting) accompanied by presyncope or syncope.

    Ara h 2 Testing for Peanut Allergy

    Ara h 2 specific IgE testing is considered medically necessary when peanut allergy is suspected and can aid diagnostic evaluation.

    Ara h 2 testing for persons with suspected peanut allergy.

    Allergy Re-testing and Repeat Percutaneous Testing

    Routine allergy re-testing and repeat percutaneous testing are limited.

    Repeat percutaneous testing is allowed if new sensitivities emerge during or after allergen immunotherapy, or if the person has failed to respond to allergen immunotherapy.
    Routine repeated percutaneous allergy testing for monitoring response to immunotherapy is considered not medically necessary.

    Performance of Both Percutaneous and IgE RAST for Same Allergens

    Performing both percutaneous (skin prick) testing and IgE serologic testing for the same allergens is generally not necessary.

    Performance of both percutaneous allergy tests and IgE RAST tests (blood) for the same allergens is considered not medically necessary.

    Allergy Immunotherapy (General)

    Allergy immunotherapy (subcutaneous) is considered medically necessary for selected IgE-mediated conditions when specific criteria are met.

    Covered indications include allergic (extrinsic) asthma, dust mite atopic dermatitis, Hymenoptera venom sensitivity, mold-induced allergic rhinitis, perennial rhinitis, seasonal allergic rhinitis or conjunctivitis.
    Required conditions: member has severe seasonal or perennial IgE-dependent symptoms after natural exposure AND BOTH of the following are met: member has skin test and/or serologic evidence of IgE-mediated sensitivity to a potent extract of the allergen; and avoidance or pharmacologic therapy cannot control symptoms or causes unacceptable side effects. OR
    Life-threatening IgE-mediated allergy to insect stings (bees, hornets, wasps, fire ants). OR
    Hypersensitivity to allergens that cannot be managed by medication or avoidance.
    Allergy immunotherapy is considered experimental and investigational for all other indications.

    Rapid Desensitization (rush, cluster, acute)

    Rapid desensitization (rush, cluster, acute) may be medically necessary in specific situations; preparations and premedication considerations apply.

    Indications (ANY): allergy to a particular drug that cannot be treated effectively with alternative medications; insect sting hypersensitivity (hymenoptera); members with moderate to severe allergic rhinitis who need treatment during or immediately before the season.
    Operational notes: allergens should be individually prepared for the patient and based on appropriate skin or in vitro testing. Rapid desensitization is considered experimental and investigational for other indications. If pregnancy is contemplated and initiation of immunotherapy is required, rapid desensitization is an acceptable approach.
    Premedication and procedural notes: premedication regimens (antihistamines, corticosteroids) may be used per protocol to reduce reaction risk; specific premedication for RDD to paclitaxel and other agents should follow published clinical guidance and be documented in the medical record.

    Epinephrine Kits

    Epinephrine auto-injector kits are indicated to prevent or treat anaphylactic reactions in high-risk individuals.

    Persons with a history of life-threatening reactions to insect stings, foods, drugs, or other allergens.
    Individuals with severe asthma at risk for anaphylaxis.
    Individuals who require epinephrine during immunotherapy.
    Epinephrine kits are considered experimental and investigational for indications other than those listed above.

    Experimental and Investigational - Tests and Procedures

    Aetna considers many tests and procedures experimental and investigational for allergy evaluation when there is insufficient evidence of effectiveness.

    Examples of tests/procedures considered experimental/investigational include (but are not limited to): ALCAT test, IgG4 and other unproven antibody or leukocyte activation assays for routine allergy diagnosis, commercial/novel unvalidated products (e.g., Allergenex, Alzair Allergy Blocker, MBG AlerjSTOP), autologous whole-blood or serum acupoint injection for chronic urticaria, ligelizumab for chronic spontaneous urticaria (investigational unless otherwise approved), skin patch testing for irritable bowel syndrome, intradermal testing to foods (not appropriate due to high false-positive rate and risk of anaphylaxis), intradermal grass pollen immunotherapy and other intradermal immunotherapy approaches that lack evidence, subcutaneous depot steroids or intramuscular depot steroids for allergic rhinitis, chemical cautery (silver nitrate) of nasal mucosa for allergic rhinitis, oral immunotherapy (OIT) for peanut allergy outside established protocols or clinical programs.
    Operational note: Documentation in the medical record must support clinical indications, prior therapies tried, rationale for experimental/novel testing if used (including review of evidence and informed consent), and any prior authorization when required.

    Clinical statements / guidance and Documentation requirements

    Additional clinical and operational guidance and documentation requirements to support medical necessity and proper billing.

    Documentation requirements: clearly document history of allergic symptoms, exposures, prior conservative therapy and response, physical findings, indication for specific test, and why alternative testing (or discontinuation of suppressive medications) is not feasible when applicable.
    Clinical guidance summary: diagnostic cut-offs and interpretation should follow validated, peer-reviewed sources; use component-resolved diagnostics (e.g., Ara h 2) where evidence supports improved specificity for clinical decision-making.
    Special populations/conditions: for food protein-induced enterocolitis syndrome (FPIES), diagnosis is primarily clinical and oral food challenge under controlled conditions may be required; skin testing and specific IgE testing are of limited value for typical FPIES.
    Percutaneous testing after immunotherapy: repeat percutaneous testing is permitted for new sensitivities or lack of response to immunotherapy; routine percutaneous testing solely for monitoring immunotherapy response is not medically necessary.
    Percutaneous skin prick and sIgE testing for food allergy: interpretation should use validated diagnostic cut-offs where available (e.g., egg, peanut component testing) and consider pre-test probability; avoid intradermal testing to foods.
    Commercial/novel products: use only products with demonstrated clinical validity and regulatory clearance; unvalidated commercial products are considered investigational.
    Billing and prior authorization: ensure allergen preparations, number of tests, immunotherapy services, and rapid desensitization procedures are supported by documentation and prior authorization when required by the payer.
    Recordkeeping: maintain test results, informed consent for higher-risk procedures (e.g., oral food challenge, rapid desensitization), details of allergen extracts/preparations, lot numbers when relevant, and monitoring/treatment provided for adverse events.

    Not Covered / Experimental Tests and Treatments

    Coding

    Covered CPT codes (when selection criteria met) - Percutaneous tests and relatedCPTCovered
    95004Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report by a physician, specify number of tests [not covered AFTER allergen immunotherapy]
    95017Allergy testing, any combination of percutaneous and intracutaneous, sequential and incremental, with venoms, immediate type reaction, including test interpretation and report, specify number of tests [not covered AFTER allergen immunotherapy]
    95018Allergy testing, any combination of percutaneous and intracutaneous, sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests [not covered AFTER allergen immunotherapy]
    Covered CPT codes - IntradermalCPTCovered
    95024Intracutaneous (intradermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report by a physician, specify number of tests
    95027Intradermal tests, sequential and incremental, with allergenic extracts for airborne allergens, immediate type reaction, including test interpretation and report by a physician, specify number of tests
    95028Intracutaneous (intradermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests
    Covered CPT codes - SETCPTCovered
    95027Intracutaneous (intradermal) sequential and incremental tests for airborne allergens (used for SET when criteria met)
    Covered CPT codes - Patch/Photo tests/Photo patchCPTCovered
    95044Patch or application tests(s) (specify number of tests)
    95052Photo patch test(s) (specify number of tests)
    95056Photo tests
    Covered CPT codes - Bronchial challenge and related pulmonary codesCPTCovered
    95070Inhalation bronchial challenge testing; with histamine, methacholine, or similar compounds
    95071Inhalation bronchial challenge testing with antigens or gases, specify
    94150Vital capacity, total (separate procedure)
    94200Maximum breathing capacity, maximum voluntary ventilation
    94621Pulmonary stress testing; complex
    94680Oxygen uptake, expired gas analysis; rest and exercise, direct, simple
    94681Including CO2 output, percentage oxygen extracted
    94690Rest, indirect (separate procedure)
    94726Plethysmography for determination of lung volumes and airway resistance
    94729Diffusing capacity
    1–10 of 11
    1/2
    Covered HCPCS codes - Bronchial challenge agentHCPCSCovered
    J7674Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
    Covered CPT codes - Exercise challenge testing and spirometryCPTCovered
    94010Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s)
    94060Bronchodilation responsiveness, spirometry pre- and post-bronchodilator
    94070Bronchospasm provocation evaluation, multiple spirometric determinations
    94617Exercise test for bronchospasm, including pre- and post-spirometry, ECG, and pulse oximetry
    94618Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration
    96419Exercise test for bronchospasm including pre- and post-spirometry and pulse oximetry; without ECG recording(s)
    Covered CPT codes - Ingestion (Oral) ChallengeCPTCovered
    95076Ingestion challenge test; initial 120 minutes of testing
    95079Each additional 60 minutes of testing (add-on)
    Covered CPT/HCPCS codes - In vitro IgE tests and specific codesmixedCovered
    83516Immunoassay for analyte other than infectious agent antibody or antigen, qualitative or semiquantitative; multiple step method
    83518Single step method (e.g., reagent strip)
    83519Immunoassay, analyte quantitative; by radiopharmaceutical technique (eg, RIA)
    83520Immunoassay, not otherwise specified
    86003Allergen specific IgE; quantitative or semi-quantitative, each allergen [covered up to 40 inhalant or 12 food/other tests]
    86005Qualitative, multi-allergen screen [covered up to 40 inhalant or 12 food/other tests]
    86008Allergen specific IgE; recombinant or purified component, each [covered up to 40 inhalant or 12 food/other tests]
    Covered CPT code - Total Serum IgECPTCovered
    82785Gammaglobulin; IgE
    Covered CPT code - Lymphocyte transformation (specific non-allergy indication)CPTCovered
    86353Lymphocyte transformation, mitogen or antigen induced blastogenesis (covered for beryllium sensitivity and certain immunodeficiency/transplant indications; not covered for in-vitro metal allergy testing)
    Covered CPT codes - Allergy immunotherapy (professional services)CPTCovered
    95115-95170Professional services for allergen immunotherapy (except home administration) [not covered for intradermal grass pollen immunotherapy or intranasal immunotherapy; immunotherapy for tree nut allergy not FDA-approved]
    95199Unlisted code for allergen immunotherapy services
    Covered HCPCS codes - EpinephrineHCPCSCovered
    J0171Injection, adrenalin, epinephrine, 0.1 mg
    J0173Injection, epinephrine (belcher) not therapeutically equivalent to J0171, 0.1 mg
    Other HCPCS/CPT related (medical benefit) and ICD-10 covered codesmixedCovered
    J2357Injection, omalizumab, 5 mg (related CPB referenced)
    ICD-10 J30.1-J30.9Allergic rhinitis
    ICD-10 L20.84Intrinsic (allergic) eczema
    ICD-10 L25.4Unspecified contact dermatitis due to food in contact with skin
    ICD-10 L27.2Dermatitis due to ingested food
    ICD-10 L50.0Allergic urticaria
    ICD-10 T50.995+Adverse effect of other drugs, medicaments and biological substances
    Not covered / Experimental CPT/HCPCS codes (examples listed)mixedExperimental
    0165UPeanut allergen-specific IgE and quantitative assessment of 64 epitopes using ELISA (VeriMAP Peanut Dx) - not covered
    0178UPeanut allergen-specific quantitative assessment of multiple epitopes using ELISA - not covered
    82784Gammaglobulin (immunoglobulin) IgA, IgD, IgG, IgM, each - listed not covered for some indications
    82787Immunoglobulin subclasses - not covered for IgG4 testing
    86258Gliadin (deamidated) antibody - listed not covered in mediator/cytotoxic testing section
    86343Leukocyte histamine release test (LHR) - listed not covered for routine allergy testing
    95060Ophthalmic mucous membrane tests - listed not covered
    A7023Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical - HCPCS not covered
    Neutral - No specific procedure codes providedmixed
    No codes listed

    Provider Actions and Operational Requirements

    Prior Authorization

    Selection criteria required for testing

    Selection criteria required for allergy testing. Testing should only be performed when all three core selection criteria are met to ensure clinical relevance and evidence-based use of diagnostics.

    • Symptoms are not adequately controlled by empiric conservative therapy (uncontrolled symptoms).
    • Testing findings must correlate to the member's history, risk of exposure and physical findings.
    • Test technique and allergens tested must have proven efficacy demonstrated through peer-reviewed scientific studies (evidence-based diagnostic testing).
    Documentation Required

    Documentation requirements for testing and immunotherapy

    Document specific clinical indications and required elements in the medical record for specialty tests and procedures. Maintain clear, contemporaneous documentation to support medical necessity, timing, and services billed.

    • Document indication for alpha-gal testing: history of delayed urticaria/angioedema/anaphylaxis or gastrointestinal symptoms with presyncope/syncope within ~3–6 hours after ingesting mammalian meat.
    • Confirm IgE-mediated allergy before initiating immunotherapy: positive skin test and/or serologic evidence to a relevant, potent extract correlated with clinical history.
    • Medical record documentation required: symptom history, prior conservative therapies and response, exposure history, test rationale, signed consent when applicable, and monitoring/administration location.
    • Separate E/M documentation required when billing evaluation and management on the same day as immunotherapy: ensure distinct, reportable E/M content/time is documented independent of immunotherapy visit.
    • Include specifics for venom immunotherapy: number of venoms to be treated, vials required, and schedule justification in the record.
    Billing Rule

    Billing rules and limits

    Billing and utilization limits and rules that affect ordering and reimbursement of allergy tests and related items. Follow code-specific limits and restrictions.

    • Limit counts for in vitro specific IgE testing: up to 40 inhalant tests (e.g., 86003) and up to 12 food/other tests (e.g., 86005/86008) for an initial allergy screen; additional tests only if initial screen positive.
    • Percutaneous tests (skin prick) are not medically necessary when performed after initiation of immunotherapy for routine monitoring (CPT 95004, 95017, 95018). Repeat percutaneous testing is allowed only if new sensitivities are suspected during/after immunotherapy or if the patient failed to respond to immunotherapy.
    • Avoid billing simultaneous blood and skin testing for the same allergens (see denial risk) — performance of both percutaneous allergy tests and IgE RAST tests (blood) for the same allergens is considered not medically necessary.
    • Epinephrine auto-injector prescribing: epinephrine kits (e.g., EpiPen) are medically necessary for those with prior life-threatening reactions or severe asthma or during immunotherapy as clinically indicated — ensure documentation if there are billing implications.
    • Depot intramuscular steroid injections for allergic rhinitis: claims may be denied as not medically necessary for routine AR management (risk of depot steroid denial).
    Denial Risk

    Denial risk highlights

    Denial risks and common reasons for noncoverage. Ensure testing and procedures are supported by clinical history and evidence-based indications to avoid denials.

    • Not medically necessary: simultaneous blood (in vitro IgE) and skin testing for the same allergens (e.g., CPT 95004 and 86003) — duplication without justification may be denied.
    • Use of experimental or unproven tests may be denied — examples include ALCAT and other tests listed in the experimental and investigational section (refer to policy experimental list). Novel or proprietary assays lacking peer-reviewed validation require strong evidence-based justification.
    • Claims for depot intramuscular steroid injections for allergic rhinitis may be denied as not medically necessary; document alternatives tried and rationale if used.
    Prior Authorization

    Prior authorization and administration requirements for immunotherapy and novel therapies

    Certain immunotherapy administrations and novel therapies require facility capability, trained personnel, and/or prior authorization. Novel or non-standard immunotherapies require explicit prior authorization and evidence-based justification.

    • Facility and personnel requirements for immunotherapy: must be administered in a medical facility with trained staff and equipment available to manage anaphylaxis (e.g., immediate access to epinephrine, oxygen, resuscitation equipment).
    • Administration and monitoring requirements: observe patients for an appropriate period post-injection per standard practice and document monitoring and any adverse events.
    • Prior authorization required for novel or nonstandard therapies: intradermal immunotherapy, oral immunotherapy (OIT), sublingual immunotherapy (SLIT) initiation/maintenance in non-standard situations, and intranasal immunotherapy — these require evidence-based justification and prior authorization.
    • Considerations for SLIT initiation and monitoring: follow guideline-endorsed dosing and monitoring recommendations; document patient selection, counseling on adverse events, and plan for management of systemic reactions.
    Documentation Required

    Documentation for BAT and specialized in‑vitro tests

    Specialized in‑vitro tests and basophil activation testing (BAT) have operational and interpretation requirements. Limited standardization and pre-analytic handling can affect validity; document handling and interpretive context.

    • BAT and specialized in‑vitro assays require timely specimen handling and validated laboratory procedures; operational requirement example: whole blood samples for BAT may need processing within 24 hours per laboratory instructions.
    • Limited standardization: emphasize that many specialized tests lack widespread standardization and should be used only when they will change management; document why conventional testing or oral food challenge (OFC) is not appropriate.
    • Guidance on interpreting Chronic Urticaria Index and similar assays: include clinical correlation and acknowledge limitations in prognostication; document how results will impact clinical decision-making.
    • Avoid routine specific IgE testing for FPIES; use OFC as the gold standard for food allergy diagnosis when appropriate, and document rationale if specialized testing is used.

    Background and Evidence Summary

    Background: The CPB summarizes evidence and clinical guidance across many domains. It affirms established diagnostic standards (skin testing and in‑vitro sIgE when indicated) and emphasizes that the oral food challenge (OFC) remains the diagnostic gold standard for IgE‑mediated food allergy. It also outlines settings where in‑vitro testing is preferred (e.g., patients on suppressive meds, widespread skin disease, uncooperative patients, risk of anaphylaxis) and repeats the initial in vitro screen limits of 40 inhalant / 12 food/other tests with additional testing allowed only if initial screen positive.

    Evidence highlights: Sublingual immunotherapy (SLIT) has moderate evidence of efficacy for allergic rhinitis/asthma from multiple RCTs and systematic reviews (symptom and medication reductions), but heterogeneity and methodological issues remain; safety concerns include frequent local oral reactions and rare anaphylaxis reports (see SLIT systematic reviews and trials).

    Oral immunotherapy (OIT) for food allergy increases desensitization rates but also substantially increases harms: the PACE meta-analysis found higher anaphylaxis risk (RR ~3.12), increased epinephrine use (RR ~2.21) and more serious adverse events; benefits versus harms are unclear.

    Ara h 2 guidance: For suspected peanut allergy when a single diagnostic test is used, Ara h 2 component testing is suggested because it offers higher specificity (but lower sensitivity) compared with SPT or whole‑allergen sIgE.

    Alpha‑gal (mammalian meat) evidence: Multiple observational studies support measuring alpha‑gal specific IgE in patients with delayed reactions (typically 3–6 hours after mammalian meat ingestion) presenting with urticaria/angioedema/anaphylaxis or GI symptoms with presyncope; skin tests with commercial meat extracts may be insensitive and sIgE is generally detectable.

    Basophil Activation Test (BAT): Meta‑analytic data indicate BAT has relatively high specificity and good sensitivity as an adjunctive in immediate drug hypersensitivity and other settings (pooled sensitivity ~78%, specificity ~95%), but larger studies and standardization are needed and BAT is listed among tests considered experimental for routine allergy evaluation in this policy.

    Depot (intramuscular) steroid risks: Observational registry data associate depot steroid injections for rhinitis with increased risk of systemic harms (e.g., diabetes RR ~1.5 and osteoporosis RR ~1.2), and guidelines recommend against routine IM depot steroids for allergic rhinitis.

    Diagnostic standards and testing caveats: The policy reiterates that SPT and sIgE have good sensitivity but limited specificity; suggested literature cut‑offs exist for foods (e.g., egg and cow’s milk) but are variable and require local validation; when uncertainty persists, perform supervised OFC as the definitive diagnostic test.

    EvidenceKey point / result
    SLIT systematic review (Lin et al 2013)63 RCTs (n=5,131): moderate evidence SLIT improves asthma and rhino‑conjunctivitis symptoms, reduces medication use; local reactions frequent, anaphylaxis not reported in review
    SLIT Cochrane review (Calderon et al 2011)42 trials (n=3,958): SLIT reduced ocular symptom scores and some individual symptoms; heterogeneity and quality concerns
    House dust mite SLIT RCT (Virchow et al, 2016)Reduced risk of moderate/severe asthma exacerbation during ICS reduction: HR 0.72 (6 SQ‑HDM) and 0.69 (12 SQ‑HDM); AEs mainly mild‑to‑moderate oral symptoms
    OIT PACE harms (Chu et al, 2019)Peanut OIT increases desensitization but also increases anaphylaxis (RR 3.12), epinephrine use (RR 2.21), and serious AEs; benefits vs harms unclear
    Ara h 2 guidance (AAAAI 2020)Ara h 2 suggested when a single diagnostic test is used — greater specificity but lower sensitivity than SPT or sIgE
    Alpha‑gal observational evidence (multiple studies, e.g., Wilson 2019, Mullins 2012)Alpha‑gal specific IgE detectable in most affected patients; delayed reactions typically 2–6 hours after mammalian meat ingestion; useful diagnostic marker when history fits
    Basophil activation test meta‑analysis (Cuervo‑Perez et al, 2014)BAT sensitivity ~78% (95% CI 74–81), specificity ~95% (95% CI 83–100); sIgE sensitivity ~72%, specificity ~90% — BAT is a useful adjunct but protocols need standardization
    Chronic Urticaria (CU) Index studies (Viswanathan et al 2012; Cho et al 2013)CU Index associated with refractory CIU (odds ratio ~4.5 in one retrospective study) but clinical utility and standardization limited
    Depot steroid risks (Aasbjerg et al, 2013)Retrospective registry study associated depot steroid injections for rhinitis with increased risk of diabetes (RR 1.5) and osteoporosis (RR 1.2); recommendation to avoid depot steroids for rhinitis
    Intradermal grass pollen RCT (Slovick et al, 2017)No clinical efficacy; intradermal therapy associated with worse nasal and asthma symptoms and immunologic priming — not recommended
    Ligelizumab phase II (Maurer et al, 2019)Dose‑finding RCT: 72 mg and 240 mg showed higher rates of complete control at week 12 versus omalizumab and placebo; needs phase III confirmation
    SLIT safety/pediatric evidence summaries (various systematic reviews/meta‑analyses)Overall SLIT evidence mixed; moderate support for efficacy but heterogeneity and methodological issues; pediatric evidence insufficiently robust
    Epicutaneous/in vitro testing and component diagnostics (background evidence)Component testing (eg, Ara h 2) promising for peanut; many novel molecular/epitope assays under study but not yet universally adopted for routine use

    Definitions

    TermDefinition
    SETSkin Endpoint Titration, also known as intradermal dilutional testing (IDT), used to determine starting dose for immunotherapy.
    SCITSubcutaneous immunotherapy (allergy shots) involving repeated administration of specific allergens by injection.
    SLITSublingual immunotherapy involving administration of allergen extracts under the tongue.
    MRTMediator Release Test—measures aggregate release of inflammatory mediators from leukocytes after exposure to foods/additives.
    EPD / LDAEnzyme potentiated desensitization / Low dose allergens—non‑FDA‑approved immunotherapy approaches using enzyme‑enhanced small allergen doses.
    Alpha-gal (galactose-α-1,3-galactose)A carbohydrate epitope in non‑primate mammalian meats associated with delayed IgE‑mediated allergic reactions.
    Chronic Urticaria (CU) IndexA basophil‑activation based assay to detect functional autoantibodies associated with chronic idiopathic urticaria.
    BATBasophil activation test — in‑vitro functional assay measuring basophil activation markers (e.g., CD63, CD203c) upon allergen/drug stimulation.
    LTTLymphocyte transformation test — in‑vitro test for metal allergy assessing lymphocyte proliferation; clinical utility for implant decisions is unproven.
    OITOral immunotherapy — controlled exposure to food allergens aiming to induce desensitization or tolerance.
    FPIESFood protein-induced enterocolitis syndrome — non‑IgE-mediated food allergy causing GI symptoms.
    sIgESerum food-specific immunoglobulin E testing.
    OFCOral food challenge - the gold standard test for diagnosis of IgE‑mediated food allergy.
    SPTSkin prick test.
    PbPPrick by prick testing.
    Ara h 2Peanut component (Ara h 2) component‑resolved diagnostic; suggested when a single diagnostic test is used—higher specificity but lower sensitivity than SPT/sIgE.
    Mediator Release Test (MRT)See MRT — measures aggregate mediator release; manufacturer claims unvalidated; considered experimental/investigational.
    sIgE (specific immunoglobulin E)Specific immunoglobulin E.

    Thresholds and Diagnostic Interpretation

    Revision History